DAVID M. MOTT - 11 Jun 2021 Form 4 Insider Report for Epizyme, Inc.

Role: Director
Signature: /s/ John Weidenbruch, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 11 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 15 Jun 2021, 16:35:54 UTC
Next filing: 21 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EPZM	Common Stock, par value $0.0001	Award	$0	+8,060	+5.2%	$0.000000	161,687	11 Jun 2021	Direct	F1
holding	EPZM	Common Stock, par value $0.0001						106,959	11 Jun 2021	See Note	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EPZM	Stock Option (Right to Buy)	Award	$0	+40,559		$0.000000	40,559	11 Jun 2021	Common Stock	40,559	$8.53	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 8,060 restricted stock units ("RSUs") granted on June 11, 2021, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full.
F2	The shares are directly held by the David Mott Declaration of Trust dated May 31, 2001 as amended (the "Mott Trust"). The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the Mott Trust shares in which the Reporting Person has no pecuniary interest.
F3	This option was granted on June 11, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full.